Contact
searchSearch
HMP Global
Login
Quiz

Stimulants and Psychosis Risk in ADHD

Edited by 
Maria Mantas
12/22/2025

Related Content

FDA building
FDA Approval
FDA Approves Centanafadine for Pediatric and Adult ADHD
07/27/2026
Maria Mantas
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug...
07/27/2026
Psych Congress Network
Viloxazine MOA Study image
News
New Study Clarifies Multimodal Mechanism of Viloxazine in ADHD
06/11/2026
New research further characterizes viloxazine’s pharmacologic profile, supporting a multimodal mechanism involving norepinephrine transporters and serotonin receptors.
New research further characterizes viloxazine’s pharmacologic profile, supporting a multimodal mechanism involving norepinephrine transporters and serotonin receptors.
New research further...
06/11/2026
Psych Congress Network
Weight scale and tape measure
News
Retrospective Cohort Study Explores Long-Term Growth Outcomes Following Pediatric Methylphenidate Use
06/11/2026
A retrospective cohort study examined the association between pediatric ADHD, methylphenidate exposure, and adult BMI and height outcomes. The findings suggest that ADHD—particularly when treated with methylphenidate—may be associated with...
A retrospective cohort study examined the association between pediatric ADHD, methylphenidate exposure, and adult BMI and height outcomes. The findings suggest that ADHD—particularly when treated with methylphenidate—may be associated with...
A retrospective cohort study...
06/11/2026
Psych Congress Network
Kids ride their bikes down a dirt path in a grassy field
Conference Coverage
d-ATS Shows Broad ADHD Efficacy in Pediatric Subgroups
06/06/2026
Brionna Mendoza
A poster presented at the 2026 Psych Congress Elevate reported that the dextroamphetamine transdermal system (d-ATS) was broadly effective for treating attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
A poster presented at the 2026 Psych Congress Elevate reported that the dextroamphetamine transdermal system (d-ATS) was broadly effective for treating attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
A poster presented at the 2026...
06/06/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Desiree Matthews, PHMNP-BC; Amber Hoberg, MSN, APRN, PMHNP-BC
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use